Clinical Trials Directory

Trials / Terminated

TerminatedNCT01271114

Hypertonic Saline and Terlipressin for Sepsis-associated Hypotension

Hypertonic Saline and Terlipressin Linked To an Early Goal-Driven Protocol for Septic Shock or Sepsis-Associated Hypotension: A Pilot Trial (HYSATESS)

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
21 (actual)
Sponsor
Hospital General de Ciudad Real · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

In hypotensive septic patients with controlled source, an hemodynamic management protocol including hypertonic saline (HS)and terlipressin improves MOD (Multiple Organ Dysfunction) Score by at least 3 points compared to the use of physiologic saline and norepinephrine. The appropriate design for this trial would be factorial. For the time being, will consider de intervention as a whole unit for this pilot study. In the future an appropriately sized factorial multicentric study shall be necessary. Other goals of the pilot study: 1. HS restores preload parameters adequately 2. HS associated with terlipressin normalizes blood pressure in septic shock 3. HS associated with terlipressin maintains plasma sodium levels 130-155mEq/L 4. There is an inverse relationship between plasma sodium and procalcitonin levels 5. HS increases plasma levels of vasopressin (AVP) 6. HS rises levels of cortisol but not of adrenocorticotropic hormone (ACTH)

Conditions

Interventions

TypeNameDescription
DRUGHypertonic Saline and TerlipressinHypertonic saline 3% 7mL/Kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation more than 10%; Terlipressin infusion (dilution 1mg in 100mL) triggered by MAP below 70 mmHg for a goal MAP above 70 mmHg
DRUGNormal saline and norepinephrineNormal saline IV bolus 7mL/kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation above 10%; Norepinephrine drip (80 micrograms/mL) to keep MAP at least 70 mmHg

Timeline

Start date
2012-06-01
Primary completion
2013-12-01
Completion
2013-12-01
First posted
2011-01-06
Last updated
2014-03-10

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT01271114. Inclusion in this directory is not an endorsement.